BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update.
"BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We have a clear path forward and ongoing support from the ALS community. We recently submitted an amendment to our IND, which includes updated documentation that is essential for regulatory compliance and trial integrity. We are in the process of finalization clinical trial agreements with leading academic centers and completing other necessary steps on trial execution and manufacturing. We believe that NurOwn, if approved, has the potential to become a valuable treatment option for ALS patients. Our team is fully aligned and executing with discipline to position BrainStorm for success."
Recent Highlights
NurOwn (MSC-NTF) for ALS
IND amendment on NurOwn submitted to FDA BrainStorm submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration for NurOwn. This important milestone sets the stage for the initiation of the planned Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). The trial will have a primary efficacy endpoint assessing changes in ALSFRS-R scores from baseline to week 24, and is designed to enroll approximately 200 ALS participants with early stage disease. Successful completion of the double blind part of the study (Part A) is expected to generate the clinical data to support a new BLA submission.
Phase 3b trial listed on Clinicaltrials.gov. Details of the trial, known as ENDURANCE, are now available on ClinicalTrials.gov ID NCT06973629. Included is a list of 15 clinical trial sites that are expected to participate in the trial.
NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic were delivered in a oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies."
Biomarker insights supporting NurOwn's mechanism and clinical impact presented at the 2025 ALS Drug Development Summit BrainStorm's senior leadership team (Dr. Bob Dagher, Dr. Netta Blondheim-Shraga and May Kay Turner) participated in sessions at the summit that highlighted insights and expertise gained throughout the NurOwn® development program. These sessions included a presentation on cerebrospinal fluid (CSF) biomarker pathways associated with NurOwn treatment, including their relationship to clinical outcomes and disease heterogeneity in ALS.
Financial Results for the First Quarter Ended March 31, 2025
Cash, cash equivalents, and restricted cash were approximately $1.8 million as of March 31, 2025.
Research and development expenditures, net, for the quarter ended March 31, 2025 were $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024.
General and administrative expenses for the quarter ended March 31, 2025 were approximately $1.8 million, compared to approximately $1.5 million for the quarter ended March 31, 2024.
Net loss for the quarter ended March 31, 2025, was approximately $2.9 million, as compared to a net loss of approximately $3.4 million for the quarter ended March 31, 2024.
Net loss per share for the three months ended March 31, 2025, and 2024 was $0.45 and $0.75, respectively.
Conference Call and Webcast
Monday, May 19, 2025, at 8:30 a.m. U.S. Eastern Time
Participant Numbers:
U.S. dial in: 888-506-0062
International: 973-528-0011
Participant Access Code: 621608
Webcast URL: https://www.webcaster4.com/Webcast/Page/2354/52457
The replay of the conference call can be accessed by dialing the numbers below and will be available for 14 days.
Teleconference Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Passcode: 52457
About NurOwn®
The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTSInvestors:Michael WoodPhone: +1 646-597-6983mwood@lifesciadvisors.com
Media:
Uri Yablonka, Chief Business OfficerPhone: +1 917-284-2911uri@brainstorm-cell.com
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
(Except share data)March 31,December 31,
20252024
UnauditedAudited
U.S. $ in thousands
ASSETSCurrent Assets:
Cash and cash equivalents$
1,644$
187
Other accounts receivable
67
63
Prepaid expenses and other current assets
621
135
Total current assets$
2,332$
385Long-Term Assets:
Prepaid expenses and other long-term assets $
22$
22
Restricted Cash
182
184
Operating lease right of use asset (Note 4)
653
807
Property and Equipment, Net
382
434
Total Long-Term Assets$
1,239$
1,447Total assets$
3,571$
1,832LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities:
Accounts payables$
6,797$
6,080
Accrued expenses
538
619
Short-term loans (Note 7)
1,200
300
Operating lease liability (Note 4)
443
549
Employees related liability
1,923
1,430
Total current liabilities$
10,901$
8,978Long-Term Liabilities:
Operating lease liability (Note 4)
127
171
Warrants liability (Note 5)
-
447
Total long-term liabilities$
127$
618Total liabilities$
11,028$
9,596Stockholders' Deficit:
Stock capital: (Note 6)
15
14
Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at March 31, 2025 and at December 31, 2024 respectively; Issued and outstanding: 7,911,204 and 6,141,762 shares at March31, 2025 and December 31, 2024 respectively (*)
Additional paid-in-capital
222,144
218,974
Treasury stocks
(116)
(116)
Accumulated deficit
(229,500)
(226,636)
Total stockholders' deficit$
(7,457)$
(7,764)Total liabilities and stockholders' deficit$
3,571$
1,832
The accompanying notes are an integral part of the consolidated financial statements.
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
U.S. dollars in thousands
(Except share data)
Three months ended March 31, 20252024Unaudited
Operating expenses:Research and development, net
$
1,304$
961
General and administrative1,785
1,513
Operating loss(3,089)
(2,474)
Financial income, net46
13
Loss on change in fair value of Warrants liability (Note 6)(179)
(940)
Net loss
$
(2,864)$
(3,401)
Basic and diluted net loss per share from continuing operations
$
(0.45)$
(*) (0.75)
Weighted average number of shares outstanding used in computing basic and diluted net loss per share6,342,002
(*) 4,315,903
The accompanying notes are an integral part of the consolidated financial statements.
Logo: https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-announces-first-quarter-2025-financial-results-and-provides-corporate-update-302456908.html
SOURCE BrainStorm Cell Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Boston Scientific Stock Outlook: Is Wall Street Bullish or Bearish?
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally. With a market cap of $157.9 billion, the company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, and more. Shares of this medTech giant have outperformed the broader market over the past year. BSX has gained 41.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.6%. In 2025, BSX stock is up 17.5%, surpassing the SPX's 7.8% rise on a YTD basis. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in further, BSX's outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has gained about 9% over the past year. Moreover, BSX's double-digit gains on a YTD basis outshine the ETF's 2.3% gains over the same time frame. BSX's strong performance can be credited to its robust product portfolio and dedicated global team. Key achievements in the second quarter include FDA approval for expanding the FARAPULSE PFA System, initiation of the ReMATCH IDE trial, and securing CE Mark for the WATCHMAN FLX Pro device in Europe. The company also finalized the acquisitions of Intera Oncology and SoniVie, enhancing its offerings in liver cancer and hypertension treatment technologies. On Jul. 23, BSX shares closed up more than 4% after reporting its Q2 results. Its adjusted EPS of $0.75 beat Wall Street's expectations of $0.72. The company's revenue was $5.1 billion, exceeding Wall Street forecasts of $4.9 billion. The company expects full-year adjusted EPS in the range of $2.95 to $2.99. For the current fiscal year, ending in December, analysts expect BSX's EPS to grow 18.7% to $2.98 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 30 analysts covering BSX stock, the consensus is a 'Strong Buy.' That's based on 27 'Strong Buy' ratings, two 'Moderate Buys,' and one 'Hold.' This configuration is more bullish than two months ago, with 26 analysts suggesting a 'Strong Buy.' On Jul. 24, Raymond James Financial, Inc. (RJF) analyst Jayson Bedford maintained a 'Buy' rating on BSX with a price target of $124, implying a potential upside of 18.2% from current levels. The mean price target of $124.53 represents an 18.7% premium to BSX's current price levels. The Street-high price target of $140 suggests an ambitious upside potential of 33.4%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
3 hours ago
- Yahoo
Researchers develop floating solar panels that could dramatically reshape eastern US: 'Doesn't sound like a lot, but it is'
Researchers develop floating solar panels that could dramatically reshape eastern US: 'Doesn't sound like a lot, but it is' Floating solar panels placed on bodies of water can actually produce more power per square foot than land-based systems. But scientists still have a lot to learn about how this tech affects nature and nearby communities. A study reported by the Cornell Chronicle, published on June 13 in the Cell Reports Sustainability journal, looked at both the benefits and the possible downsides of using floating solar across the U.S. Northeast. The researchers started by figuring out how many waterbodies could realistically support floating solar panels. They found that about 3.5% of existing bodies of water in the region would work. If all of them were used, floating solar could supply 25% of the Northeast's solar energy needs by 2050. That would also make up for all of the land area normally needed for land-based solar. The researchers said floating solar could provide 5% of the region's solar needs while avoiding placing panels in spots important for biodiversity and recreation. Combined with existing solar installations on land, the region's solar production could improve by 194%. "Five percent doesn't sound like a lot, but it is," said senior author Steven Grodsky. "That's 5% less that you would need to generate with terrestrial solar, which equates to thousands of acres and a major boost to solar energy generation with low potential for conflict." In New York State, floating solar could contribute 55% of the state's energy needs by 2030. If areas important to biodiversity are left out, that number drops to 24%. The study also points to a possible trade-off. Grodsky's team found that floating solar increased the amount of planet-warming gases by almost 27% on small ponds. He said, "Freshwater is far rarer than land, and we may wish to consider socioecological impacts of floating photovoltaics concurrent with potential co-benefits like land sparing." Lead author Adam Gallaher said this research gives communities and decision-makers a better way to plan: "This gives policymakers and stakeholders a playbook to take a data-driven, fact-based approach to tackling multiple crises." Do you think we should place solar panels over bodies of water? Absolutely Depends on the place Depends on the cost No way Click your choice to see results and speak your mind. Floating solar means towns and energy providers will have to pay less for land and extra equipment. That can free up money for other local needs like schools and repairs. Plus, these savings can help keep energy prices stable for residents. For individuals wanting to make a difference on their own, installing solar panels is the ultimate home energy hack, because it can bring your cost of energy down to or near $0. EnergySage provides a free service that makes it easy to compare quotes from vetted local installers and potentially save up to $10,000 on solar installations. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the the daily Crossword
Yahoo
4 hours ago
- Yahoo
Studio City International Holdings Second Quarter 2025 Earnings: US$0.019 loss per share (vs US$0.17 loss in 2Q 2024)
Studio City International Holdings (NYSE:MSC) Second Quarter 2025 Results Key Financial Results Revenue: US$190.1m (up 18% from 2Q 2024). Net loss: US$3.75m (loss narrowed by 89% from 2Q 2024). US$0.019 loss per share (improved from US$0.17 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Studio City International Holdings shares are up 5.1% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 1 warning sign for Studio City International Holdings you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data
